Overview:

Growth in incidence of rectal, GI and colon cancer and flourishing trend of cancer screening through genetic testing are the prime factors allowing the growth of in vitro colorectal cancer screening market. Favorable government guidelines and regulation for increasing awareness in the general population and supporting the adoption colon cancer screening also facilitate the global demand for minimally invasive screening tests that use genetic biomarkers and DNA for risk determination. Colorectal cancer is the third most prevalent form of cancer and its incidence rate has witnessed a major upswing in the past decade.

Technological innovation in the field of IVD and molecular diagnostics and use of biomarkers have significantly urged the demand for in vitro colorectal cancer screening. Growing accuracy of in vitro diagnostic tools thus, have assisted in promoting the growth of this market. Tools such as fecal occult tests and Immuno-FOB ELISA and Immuno-FOB agglutination tests find the widest use in this market, and are majorly favored by users due to their easy applicability. Transferrin assay and methylated gene testing will witness the most rapid growth due to their recent introduction in the market and high accuracy rate over the other counterparts. Developed and high-income regions of the world will dominate the in vitro colorectal cancer screening market through the forecast period. Whereas regions such as Asia-Pacific, Latin America and Middle East and Africa will witness above average market growth.

The global in vitro colorectal cancer screening market is segmented on the following bases:       

1.    Test Types

a.    Fecal Occult Blood Tests

i.    Guaiac FOB Stool Test

ii.    Immuno-FOB Agglutination Test

iii.    Lateral Flow Immuno-FOB Test

iv.    Immuno-FOB ELISA Test

b.    Biomarker Tests

i.    Tumor M2-PK Stool Test

ii.    Transferrin Assays

c.    CRC DNA Screening Tests

i.    Methylated Gene Testing

ii.    Panel DNA Tests

2.    Geography

a.    North America

i.    US

ii.    Canada

b.    Europe

i.    UK

ii.    Germany

iii.    Rest of Europe

c.    Asia-Pacific

i.    Japan

ii.    China

iii.    Rest of APAC

d.    Latin America

e.    Middle East and Africa

Key players identified for in vitro colorectal cancer screening market include but are not limited to:

Quest Diagnostics Incorporated, Sysmex Corporation, Merck Millipore, OncoCyte Corporation-Biotime, Beckman Coulter Inc., Alere Inc., Abbott and several others

This report offers:

• An overview of the global markets forin vitro colorectal cancer screening
• Market trends assessment for the period 2014-2023, with historical information for 2014 & 2015, and projections through 2023, with respective CAGRS during 2016-2023
• Qualitative assessment tools such as market drivers, challenges and future prospects, major commercial events, etc.
• Market competition scrutiny tools such as market share analysis, attractive investment proposition, and Porter’s Five Forces model
• Focus on each level of market segmentation based on product approvals, launch, and current and anticipated market dynamics
• A general overview of the industry structure
• Company profiles highlighting key information about the major players operating in the in vitro colorectal cancer screening market